[go: up one dir, main page]

KR910700048A - 오메프라졸의 항균제로서의 용도 - Google Patents

오메프라졸의 항균제로서의 용도

Info

Publication number
KR910700048A
KR910700048A KR1019900702221A KR900702221A KR910700048A KR 910700048 A KR910700048 A KR 910700048A KR 1019900702221 A KR1019900702221 A KR 1019900702221A KR 900702221 A KR900702221 A KR 900702221A KR 910700048 A KR910700048 A KR 910700048A
Authority
KR
South Korea
Prior art keywords
methoxy
campylobacter
sulfinyl
benzimidazole
pyridinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019900702221A
Other languages
English (en)
Other versions
KR0140236B1 (ko
Inventor
마사끼 도모이
요시후미 이께다
요시꼬 요꼬다
Original Assignee
안데르스 베딘
악티에볼라게트 헤슬레
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12300238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR910700048(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 안데르스 베딘, 악티에볼라게트 헤슬레 filed Critical 안데르스 베딘
Publication of KR910700048A publication Critical patent/KR910700048A/ko
Application granted granted Critical
Publication of KR0140236B1 publication Critical patent/KR0140236B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음.

Description

오메프라졸의 항균제로서의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 캠필로박터(Campylobacter) 박테리아 감염증 치료용 의약품의 제조를 위한 5-메톡시-2-〔〔(4-메톡시-3,5-디메틸-2-피리디닐)메틸〕술피닐〕-1H-벤즈이미다졸 또는 그의 제약상 허용되는 염의 용도.
  2. 캠필로박터 감염증 환자에게 5-메톡시-2-〔〔(4-메톡시-3,5-디메틸-2-피리디닐)메틸〕술피닐〕-1H-벤즈이미다졸 또는 그의 제약상 허용되는 염을 캠필로박터 감염증 치료에 충분한 양으로 투여하는 것으로 이루어진 캠필로박터 감염증 치료 방법.
  3. 활성 성분이 5-메톡시-2-〔〔(4-메톡시-3,5-디메틸-2-피리디닐)메틸〕술피닐〕-1H-벤즈이미다졸 또는 그의 제약상 허용되는 염인 캠필로박터 감염증 치료용 약제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900702221A 1989-02-09 1990-02-02 오메프라졸의 항균제로서의 용도 Expired - Fee Related KR0140236B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP1030311A JP2694361B2 (ja) 1989-02-09 1989-02-09 抗菌剤
JP1/30311 1989-02-09
PCT/SE1990/000070 WO1990009175A1 (en) 1989-02-09 1990-02-02 Use of omeprazole as an antimicrobial agent

Publications (2)

Publication Number Publication Date
KR910700048A true KR910700048A (ko) 1991-03-13
KR0140236B1 KR0140236B1 (ko) 1998-06-01

Family

ID=12300238

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900702221A Expired - Fee Related KR0140236B1 (ko) 1989-02-09 1990-02-02 오메프라졸의 항균제로서의 용도

Country Status (19)

Country Link
US (1) US5093342A (ko)
EP (1) EP0414847B1 (ko)
JP (1) JP2694361B2 (ko)
KR (1) KR0140236B1 (ko)
AT (1) ATE94063T1 (ko)
AU (1) AU626641B2 (ko)
CA (1) CA2025668C (ko)
CY (1) CY1909A (ko)
DE (1) DE69003207T2 (ko)
DK (1) DK0414847T3 (ko)
ES (1) ES2058892T3 (ko)
HK (1) HK52196A (ko)
HU (1) HU205253B (ko)
IE (1) IE65814B1 (ko)
IL (1) IL93263A0 (ko)
LV (1) LV10577B (ko)
MY (1) MY111737A (ko)
PH (1) PH26787A (ko)
WO (1) WO1990009175A1 (ko)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69014141T2 (de) * 1989-02-10 1995-05-24 Takeda Chemical Industries Ltd Verwendung von Benzimidazol-Derivaten als antibakterielle Mittel.
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
JPH06500547A (ja) * 1990-09-14 1994-01-20 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング ピリジルメチルスルフィニル―１ｈ―ベンゾイミダゾール誘導体のヘリコバクターにより起こされる病気の治療のための使用
IS3990A (is) * 1992-04-24 1993-10-25 Ab Astra Aðferð við að blanda saman efni sem hindrar flæðimagasýru og bakteríueyðandi efnis sem brotnar niður í súru umhverfi
US5504082A (en) * 1992-06-01 1996-04-02 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and pharmaceutical compostions
EP0673246A1 (de) * 1992-12-10 1995-09-27 Byk Gulden Lomberg Chemische Fabrik GmbH Verwendung von alkylthiopyridinen zur bekämpfung von heliobacter-bakterien
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
WO1996024342A1 (en) * 1995-02-07 1996-08-15 Narayan Krishnarao Athanikar Concomitant treatment with oral bismuth compounds
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
DE69821976T2 (de) * 1997-12-08 2004-12-16 Altana Pharma Ag Neue suppositoriumsform mit säureempfindliche wirkstoffe
AU2031799A (en) 1998-01-14 1999-08-02 Uab Research Foundation, The Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6780880B1 (en) * 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
EP1603537A4 (en) * 2003-02-20 2009-11-04 Santarus Inc NOVEL FORMULATION, ANTICIPATED COMPLEX IMMEDIATE RELEASE FOR A FAST AND CONTINUOUS SUPPRESSION OF MAGIC ACID
TWI337877B (en) * 2003-07-18 2011-03-01 Santarus Inc Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050037070A1 (en) * 2003-07-18 2005-02-17 Santarus, Inc. Pharmaceutical formulatins useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2528403T3 (es) 2005-04-28 2015-02-09 Proteus Digital Health, Inc. Sistemas informáticos farmacéuticos
US20090143438A1 (en) 2006-03-10 2009-06-04 Arigen Pharmaceuticals, Inc. Novel Pyridine Derivative Having Anti-Helicobacter Pylori Activity
WO2008036682A2 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
GB2444593B (en) 2006-10-05 2010-06-09 Santarus Inc Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2086543A2 (en) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US8778975B2 (en) 2006-12-18 2014-07-15 Link Geonomics, Inc. Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion
CA2752373C (en) 2009-02-20 2017-10-10 To-Bbb Holding B.V. Glutathione-based drug delivery system
AU2010235726B2 (en) 2009-04-09 2012-01-19 Link Genomics, Inc. Pyridine thio derivative, and pharmaceutical composition which contains same and has anti-Helicobacter pylori action
KR20190116576A (ko) 2009-05-06 2019-10-14 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US8722026B2 (en) * 2010-01-06 2014-05-13 Elc Management, Llc Skin lightening compositions
US8992897B2 (en) 2010-01-06 2015-03-31 Elc Management Llc Skin lightening compositions
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
KR101628474B1 (ko) * 2014-08-27 2016-06-08 경북대학교 산학협력단 오메프라졸을 유효성분으로 포함하는 피부 미백용 화장료 조성물
EP4598528A1 (en) 2022-10-04 2025-08-13 Arsenil Zabirnyk Inhibition of aortic valve calcification

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
WO1989003829A1 (en) * 1987-10-30 1989-05-05 Aktiebolaget Hässle Omeprazole for treatment of diseases related to bone loss

Also Published As

Publication number Publication date
AU626641B2 (en) 1992-08-06
MY111737A (en) 2000-12-30
ATE94063T1 (de) 1993-09-15
IE65814B1 (en) 1995-11-15
WO1990009175A1 (en) 1990-08-23
US5093342A (en) 1992-03-03
LV10577B (en) 1995-10-20
JPH02209809A (ja) 1990-08-21
PH26787A (en) 1992-10-13
AU5038190A (en) 1990-09-05
DE69003207D1 (de) 1993-10-14
IL93263A0 (en) 1990-11-29
IE900418L (en) 1990-08-09
CY1909A (en) 1990-02-02
DK0414847T3 (da) 1993-12-13
KR0140236B1 (ko) 1998-06-01
EP0414847A1 (en) 1991-03-06
HUT54890A (en) 1991-04-29
DE69003207T2 (de) 1994-02-03
JP2694361B2 (ja) 1997-12-24
HK52196A (en) 1996-03-29
ES2058892T3 (es) 1994-11-01
EP0414847B1 (en) 1993-09-08
CA2025668C (en) 1998-09-15
HU901539D0 (en) 1991-02-28
CA2025668A1 (en) 1990-08-10
HU205253B (en) 1992-04-28
LV10577A (lv) 1995-04-20

Similar Documents

Publication Publication Date Title
KR910700048A (ko) 오메프라졸의 항균제로서의 용도
BRPI0011674B8 (pt) cristal de (r)-2-[[[3-metil-4-(2,2,2-trifluoroetóxi)-2-piridinil]metil] sulfinil]-1h-benzimidazol, composição farmacêutica, e, uso do referido cristal
EP1089738A4 (en) ANTIMICROBIAL LOCKS COMPRISING DERIVATIVES OF TAURINAMIDE AND CARBOXYLIC ACIDS AND / OR THEIR SALTS
AR010361A1 (es) "S-OMEPRAZOL [ENANTIoMERO S DE 5-METOXI-2-[[(4--METOXI-3,5-DIMETIL-2-PIRIDINIL)-METIL]SULFINIL]-1H-BENCIMIDAZOL], EN UNA FORMA NEUTRA NO SALINA, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA, Y SU USO PARA LA MANUFACTURA DE MEDICAMENTOS"
FI913036A0 (fi) Terapeutiskt aktiv substituerad benzimidazol och foerfarande foer dess framstaellning.
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
BR0209103A (pt) Omeprazol forma c, processo para preparação e uso do mesmo e formulação farmacêutica
DE69302646D1 (de) Benzimidazolverbindungen als Antibiotika gegen Campylobacter pylon
NO178336C (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse og mellomprodukter
DE69125940D1 (de) Pharmazeutische zusammensetzungen die 5-difluormethoxy-2-[3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten
BR9913982A (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente ativo e seu uso no tratamento de doenças vasculares
Eneroth et al. Antibiotic concentrations in maxillary sinus secretions and in the sinus mucosa.
NO912942D0 (no) Vaksine for preventiv behandling av infeksjon av leverikte hos droevtyggere.
ATE228843T1 (de) Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit
FR2673105B1 (fr) Nouvelles compositions pharmaceutiques, notamment pour le traitement des colopathies fonctionnelles, et procedes de preparation de compositions et de medicaments, notamment pour le traitement de ces affections.
CO4950559A1 (es) Derivados de eritromicina
KR900017599A (ko) 종양 치료용 약학 조성물
KR890001555A (ko) 요산 배설용 조성물
NO996117L (no) Anordning for tilfoering av medikamenter samt behandling av virale og mikrobielle infeksjoner og taeringssyndrom
KR930007452A (ko) 벤조디아제핀-금단 환자의 불안증 치료방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20080117

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090311

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090311